Olopatadine nasal spray for the treatment of allergic rhinitis.

Olopatadine hydrochloride nasal spray (Patanase Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.
AuthorsPeter S Roland, Bradley F Marple, G Michael Wall
JournalExpert review of clinical immunology (Expert Rev Clin Immunol) Vol. 6 Issue 2 Pg. 197-204 (Mar 2010) ISSN: 1744-666X [Print] England
PMID20402382 (Publication Type: Journal Article)
Chemical References
  • Dibenzoxepins
  • Histamine H1 Antagonists, Non-Sedating
  • Olopatadine Hydrochloride
  • Activities of Daily Living
  • Administration, Intranasal
  • Clinical Trials as Topic
  • Dibenzoxepins (chemistry, pharmacology, therapeutic use)
  • Drug Approval
  • Epistaxis (etiology)
  • Histamine H1 Antagonists, Non-Sedating (adverse effects, chemistry, pharmacology, therapeutic use)
  • Nasal Obstruction
  • Olopatadine Hydrochloride
  • Quality of Life
  • Rhinitis, Allergic, Seasonal (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: